Arla targets clinical beverage market with new whey protein product03 September 2012Arla has entered the $4 billion clinical drinks market after launching a version of its Lacprodan whey which is stable at ultra high temperature (UHT) at neutral pH. Arla said that the new whey protein - Lacprodan DI-7017 - is ‘set to transform the fast-growing clinical nutrition category’ through the launch of new products targeted at elderly consumers of clinical drinks. Whey is notoriously challenging to incorporate into the process of manufacturing UHT products. The new powdered, hydrolysed whey protein is said to overcome these challenges and be more effective than other proteins at clearing the gastric chamber. Arla also claim that Lacprodan DI-7017 promotes more efficient muscle synthesis. “The total number of clinical nutrition patients is expected grow by more than 7% a year between now and 2015, primarily because of the world’s ageing population,” said Peter Schouw Andersen, Arla’s business development manager for Food Ingredients, speaking to NUTRAIngredients.com. “It is suitable in the milky beverages typically used in clinical nutrition, but can also be incorporated into less viscous beverages which may be easier for some patients to drink,” he added. | |
 Exhibitions Fi Europe | Hi/Ni China | Fi India | Fi Asia | Fi South America | Health ingredients Europe, Ni & NuW | Fi Istanbul Languages      
| |
